Literature DB >> 19015329

Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.

Benoite Kaeser1, Hagen Zandt, Fabrice Bour, Elke Zwanziger, Christophe Schmitt, Xiaoping Zhang.   

Abstract

Saquinavir, a potent human immunodeficiency virus protease inhibitor, is extensively metabolized by CYP3A4. Saquinavir is coadministered with ritonavir, a strong CYP3A4 inhibitor, to boost its exposure. Ketoconazole is a potent CYP3A inhibitor. The objectives of this study were to investigate the effect of ketoconazole on the pharmacokinetics of saquinavir/ritonavir and vice versa using the approved dosage regimens of saquinavir/ritonavir at 1,000/100 mg twice daily and ketoconazole at 200 mg once daily. This was an open-label, randomized two-arm, one-sequence, two-period crossover study in healthy subjects. In study arm 1, 20 subjects received saquinavir/ritonavir treatment alone for 14 days, followed in combination with ketoconazole treatment for 14 days. In arm 2, 12 subjects received ketoconazole treatment for 6 days, followed in combination with saquinavir/ritonavir treatment for 14 days. The pharmacokinetics were assessed on the last day of each treatment (days 14 and 28 in arm 1 and days 6 and 20 in arm 2). The exposures C(max) and the area under the concentration-time curve from 0 to 12 h (AUC(0-12)) of saquinavir and ritonavir with or without ketoconazole were not substantially altered after 2 weeks of concomitant dosing with ketoconazole. The C(max) and AUC(0-12) of ketoconazole, dosed at 200 mg once daily, were increased by 45% (90% confidence interval = 32 to 59%) and 168% (90% confidence interval = 146 to 193%), respectively, after 2 weeks of concomitant dosing with ritonavir-boosted saquinavir (1,000 mg of saquinavir/100 mg of ritonavir given twice daily). The greater exposure to ketoconazole when given in combination with saquinavir/ritonavir was not associated with unacceptable safety or tolerability. No dose adjustment for saquinavir/ritonavir (1,000/100 mg twice daily) is required when coadministered with 200 mg of ketoconazole once daily, and high doses of ketoconazole (>200 mg/day) are not recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015329      PMCID: PMC2630604          DOI: 10.1128/AAC.00769-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital.

Authors:  J Baran; B Muckatira; R Khatib
Journal:  Scand J Infect Dis       Date:  2001

2.  Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.

Authors:  Y Khaliq; K Gallicano; S Venance; S Kravcik; D W Cameron
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

Review 3.  Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.

Authors:  J G Gerber
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

Review 4.  The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; Scott R Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  J Clin Pharmacol       Date:  2003-05       Impact factor: 3.126

  4 in total
  4 in total

Review 1.  Clinically relevant drug-drug interactions between antiretrovirals and antifungals.

Authors:  Ramya Krishna Vadlapatla; Mitesh Patel; Durga K Paturi; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-02-12       Impact factor: 4.481

2.  Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.

Authors:  Morgan A Wambaugh; Steven T Denham; Magali Ayala; Brianna Brammer; Miekan A Stonhill; Jessica Cs Brown
Journal:  Elife       Date:  2020-05-05       Impact factor: 8.140

3.  Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers.

Authors:  Christophe Schmitt; Myriam Riek; Katie Winters; Malte Schutz; Susan Grange
Journal:  Arch Drug Inf       Date:  2009-03

4.  Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators.

Authors:  Sanjita Paudel; Aarajana Shrestha; Piljoung Cho; Riya Shrestha; Younah Kim; Taeho Lee; Ju-Hyun Kim; Tae Cheon Jeong; Eung-Seok Lee; Sangkyu Lee
Journal:  Pharmaceutics       Date:  2019-09-16       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.